$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009446 Filed on May 07, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.128M	$1.412M
YoY Change	-20.12%	18.62%
% of Gross Profit
Research & Development	$609.7K	$799.6K
YoY Change	-23.76%	149.88%
% of Gross Profit
Depreciation & Amortization	$938.00	$365.00
YoY Change	156.99%
% of Gross Profit
Operating Expenses	$1.737M	$2.211M
YoY Change	-21.43%	45.47%
Operating Profit	-$1.737M	-$2.211M
YoY Change	-21.43%
Interest Expense	$184.9K	$166.4K
YoY Change	11.15%	-101.25%
% of Operating Profit
Other Income/Expense, Net	-$423.3K	-$130.5K
YoY Change	224.45%	-99.02%
Pretax Income	-$2.161M	-$2.342M
YoY Change	-7.74%	-84.15%
Income Tax
% Of Pretax Income
Net Earnings	-$2.161M	-$2.342M
YoY Change	-7.74%	-84.15%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.01
Diluted Earnings Per Share	-$0.01	-$0.01
COMMON SHARES
Basic Shares Outstanding	336.9M shares	182.3M shares
Diluted Shares Outstanding	336.9M shares	183.7M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.152M	$563.9K
YoY Change	813.78%	-87.21%
Cash & Equivalents	$5.152M	$563.9K
Short-Term Investments
Other Short-Term Assets	$229.2K	$107.5K
YoY Change	113.19%	-65.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.382M	$671.4K
YoY Change	701.6%	-85.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.10K	$1.620K
YoY Change	955.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$17.10K	$1.620K
YoY Change	955.49%
TOTAL ASSETS
Total Short-Term Assets	$5.382M	$671.4K
Total Long-Term Assets	$17.10K	$1.620K
Total Assets	$5.399M	$673.0K
YoY Change	702.21%	-85.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$499.9K	$978.2K
YoY Change	-48.9%	475.39%
Accrued Expenses	$175.1K	$35.65K
YoY Change	391.29%	-83.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$103.5K
YoY Change
Total Short-Term Liabilities	$1.384M	$1.667M
YoY Change	-16.97%	-94.19%
LONG-TERM LIABILITIES
Long-Term Debt	$1.536M	$517.8K
YoY Change	196.61%	-82.21%
Other Long-Term Liabilities		$190.9K
YoY Change		-80.12%
Total Long-Term Liabilities	$1.536M	$708.7K
YoY Change	116.71%	-81.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.384M	$1.667M
Total Long-Term Liabilities	$1.536M	$708.7K
Total Liabilities	$2.920M	$2.376M
YoY Change	22.9%	-92.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$40.89M
YoY Change
Common Stock	$43.37M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.479M	-$1.703M
YoY Change
Total Liabilities & Shareholders Equity	$5.399M	$673.0K
YoY Change	702.21%	-85.74%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$2.161M	-$2.342M
YoY Change	-7.74%	-84.15%
Depreciation, Depletion And Amortization	$938.00	$365.00
YoY Change	156.99%
Cash From Operating Activities	-$1.348M	-$1.266M
YoY Change	6.47%	-11.46%
INVESTING ACTIVITIES
Capital Expenditures	$10.70K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.70K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.042M	$0.00
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-$1.348M	-$1.266M
Cash From Investing Activities	-$10.70K	$0.00
Cash From Financing Activities	$4.042M	$0.00
Net Change In Cash	$2.683M	-$1.266M
YoY Change	-311.91%	-149.46%
FREE CASH FLOW
Cash From Operating Activities	-$1.348M	-$1.266M
Capital Expenditures	$10.70K	$0.00
Free Cash Flow	-$1.359M	-$1.266M
YoY Change	7.32%	-11.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001516551
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	000-55136
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	Skye Bioscience, Inc.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0692882
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5910 Pacific Center Blvd
CY2021Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 320
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2469410	USD
CY2021Q1	dei	City Area Code CityAreaCode	949
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	480-9051
CY2021Q1	dei	Security12g Title Security12gTitle	Common Stock, par value $0.001
CY2021Q1	dei	Trading Symbol TradingSymbol	SKYE
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	371974416	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5152425	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4567	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4566	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	224608	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	190409	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	5381600	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2664385	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17099	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7341	USD
CY2021Q1	us-gaap	Assets Assets	5398699	USD
CY2020Q4	us-gaap	Assets Assets	2671726	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	499854	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	364340	USD
CY2021Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	10000	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	17032	USD
CY2021Q1	embi	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	43129	USD
CY2020Q4	embi	Accrued Interest Related Parties Current AccruedInterestRelatedPartiesCurrent	44087	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	131995	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	61547	USD
CY2021Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	103523	USD
CY2020Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	64062	USD
CY2021Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	276917	USD
CY2020Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	450000	USD
CY2021Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1072593	USD
CY2021Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	318862	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	197564	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	38567	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1384280	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	787199	USD
CY2021Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	13177	USD
CY2020Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	52638	USD
CY2021Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	450000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	931103	USD
CY2021Q1	us-gaap	Liabilities Liabilities	2920050	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2220940	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	367641082	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	367641082	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	288074415	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	288074415	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	367641	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	288074	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	43005506	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38896693	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40894498	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38733981	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	2478649	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	450786	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5398699	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2671726	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	609656	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	799612	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	1737262	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	2211208	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1127606	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1411596	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1737262	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2211208	USD
CY2021Q1	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	238350	USD
CY2020Q1	embi	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-35903	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	184905	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	166355	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-423255	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-130452	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2160517	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2160517	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2341660	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2341660	USD
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	336883489	shares
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	182256966	shares
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	336883489	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	183737415	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2160517	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2341660	USD
CY2021Q1	us-gaap	Depreciation Depreciation	938	USD
CY2020Q1	us-gaap	Depreciation Depreciation	365	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	146580	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	64142	USD
CY2021Q1	embi	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	-238350	USD
CY2020Q1	embi	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	35903	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	135514	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	141490	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	130710	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	34199	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-57290	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	807457	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-7032	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	30903	USD
CY2021Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-958	USD
CY2020Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	35645	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	70448	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-24546	USD
CY2021Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	121298	USD
CY2020Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	9484	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1348088	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1266113	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10696	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10696	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4030000	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2021Q1	embi	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	11800	USD
CY2020Q1	embi	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4041800	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2683016	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1266113	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2473976	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1834515	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5156992	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568402	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5152425	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	563864	USD
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4567	USD
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4538	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5156992	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568402	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	44087	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021Q1	embi	Exercise Of Warrants ExerciseOfWarrants	0	USD
CY2020Q1	embi	Exercise Of Warrants ExerciseOfWarrants	26563	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	548058	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64142	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2341660	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-1702897	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	450786	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	146580	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2160517	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	2478649	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40894498	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5152425	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets </span></div>and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity instruments, derivative liabilities, and debt with embedded features.
CY2021Q1	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	1877938	USD
CY2020Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	1877938	USD
CY2021Q1	embi	Research And Development Licensed Technology Costs Capitalized To Date ResearchAndDevelopmentLicensedTechnologyCostsCapitalizedToDate	0	USD
CY2021Q1	embi	Warrants Vested And Outstanding WarrantsVestedAndOutstanding	78546668	shares
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	38567	USD
CY2021Q1	embi	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	0	USD
CY2021Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	238350	USD
CY2021Q1	embi	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	0	USD
CY2021Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	276917	USD
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	501400	USD
CY2020Q1	embi	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	0	USD
CY2020Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35903	USD
CY2020Q1	embi	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	-26563	USD
CY2020Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	438934	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	90797	USD
CY2020Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	190882	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	410603	USD
CY2020Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	248052	USD
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.12
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.04
CY2021Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	43129	USD
CY2020Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	35645	USD
CY2021Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	286	USD
CY2020Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	141097	USD
CY2020Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	130347	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	393	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	363	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	184905	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	166355	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	750469	USD
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3D
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	146580	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	64142	USD

Files In Submission

Name	View Source	Status
0001628280-21-009446-index-headers.html	Edgar Link	pending
0001628280-21-009446-index.html	Edgar Link	pending
0001628280-21-009446.txt	Edgar Link	pending
0001628280-21-009446-xbrl.zip	Edgar Link	pending
embi-20210331.htm	Edgar Link	pending
embi-20210331.xsd	Edgar Link	pending
embi-20210331_cal.xml	Edgar Link	unprocessable
embi-20210331_def.xml	Edgar Link	unprocessable
embi-20210331_htm.xml	Edgar Link	completed
embi-20210331_lab.xml	Edgar Link	unprocessable
embi-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skye-20210331xex101.htm	Edgar Link	pending
skye-20210331xex101001.jpg	Edgar Link	pending
skye-20210331xex101002.jpg	Edgar Link	pending
skye-20210331xex311.htm	Edgar Link	pending
skye-20210331xex312.htm	Edgar Link	pending
skye-20210331xex321.htm	Edgar Link	pending
skye-20210331xex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2021 Q1 Form 10-Q Financial Statement

#000162828021009446 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2021 Q1 Form 10-Q Financial Statement

#000162828021009446 Filed on May 07, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye